Coagulation Factor IX Antikörper

Produktnummer ABIN1387087

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch Coagulation Factor IX in WB, IHC (p) und IF (p). Er zeigt eine Reaktivität gegenüber Human, Maus und Ratte und wurde in 1 Publikation erwähnt.

Kurzübersicht für Coagulation Factor IX Antikörper (ABIN1387087)

Target: Coagulation Factor IX (F9)

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Coagulation Factor IX Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Produktdetails anti-Coagulation Factor IX Antikörper

Kreuzreaktivität: Human, Maus, Ratte

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human Coagulation factor IXa heavy chain

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Referenzen für anti-Coagulation Factor IX Antikörper (ABIN1387087)

Yang, Bae, Jung, Park, Chung, Seok, Roh, Han, Oh, Sohn, Jeong, Cho: "Surface functionalization-specific binding of coagulation factors by zinc oxide nanoparticles delays coagulation time and reduces thrombin generation potential in vitro." in: PLoS ONE, Vol. 12, Issue 7, pp. e0181634, (2017) (PubMed).

Details zu Coagulation Factor IX

Target: Coagulation Factor IX (F9)

Andere Bezeichnung: Factor 9

Hintergrund:

Synonyms: Christmas Disease, Christmas factor, Coagulant factor IX, Coagulation factor 9, Coagulation factor IX plasma thromboplastic component, Coagulation factor IX, Coagulation factor IXa heavy chain, F9, FA9_HUMAN, Factor 9, Factor IX Deficiency, Factor9, FactorIX, FIX, GLA domain, Haemophilia B, MGC129641, MGC129642, P19 antibody Plasma thromboplastic component, Plasma thromboplastin component, PTC, Truncated coagulation factor IX.

Background: Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors X, IX, V, and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble fibrin clots and the promotion of platelet aggregation (1-3). Coagulation factor IX (plasma thromboplastic component, F9, F.IX, HEMB) is a vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor (3,4). Factor XIa mediated proteolytic cleavage of factor IX generates factor IXa, an active serine protease composed of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, linked through disulfide bonds (5). Genetic alterations at the Factor IX locus such as point mutations, insertions and deletions, can lead to hemophilia B, also known as Christmas disease (6).

Gen-ID: 2158